Literature DB >> 7521807

Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study.

P E Spronk1, H Bootsma, M G Huitema, P C Limburg, C G Kallenberg.   

Abstract

Active SLE is characterized by immune deposits and subsequent vascular inflammation in many organs. Expression and up-regulation of adhesion molecules is basic to migration of inflammatory cells into the tissues. Recently, soluble isoforms of these molecules have been described which might be an expression of their up-regulation in the tissues and, as such, of disease activity. The purpose of this study was to evaluate whether changes in levels of soluble adhesion molecules reflect disease activity. We analysed serial sera in a 6-month period preceding 22 consecutive exacerbations of SLE for levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and sE-selectin. Levels were related to clinical disease activity (SLEDAI), and levels of anti-dsDNA and complement. At the time of maximal disease activity, levels of sVCAM-1 in patients with SLE were higher than those in controls (P < 0.0001), levels in patients with renal involvement being higher than in those without (P < 0.02). Levels of sVCAM-1 correlated with SLEDAI scores (P < 0.05) and, inversely, with levels of C3 (P = 0.01). In addition, in the presence of anti-dsDNA, levels of sVCAM-1 tended to correlate with levels of these autoantibodies (P < 0.1). Levels of sICAM-1 were normal and sE-selectin levels even decreased compared with controls. Levels of sVCAM-1 were higher at the moment of relapse (P = 0.001) than at 6 months before this time point. This rise correlated with the rise in SLEDAI score (P < 0.02). Levels of sICAM-1 and sE-selectin did not rise, and remained in the normal range in all exacerbations studied. In conclusion, in contrast to sICAM-1 and sE-selectin, levels of sVCAM-1 are increased, rise parallel to disease activity during exacerbations in SLE, and are associated with decreasing levels of complement factors. This favours the hypothesis of immune deposit formation, activation of the complement cascade and activation of endothelial cells. Concurrent up-regulation of vascular adhesion molecules may thus result in transmigration of activated inflammatory cells inducing tissue damage.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521807      PMCID: PMC1534867          DOI: 10.1111/j.1365-2249.1994.tb06107.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

Review 1.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

Review 2.  Adhesion receptors of the immune system.

Authors:  T A Springer
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

3.  IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-gamma.

Authors:  M H Thornhill; D O Haskard
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

4.  Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 1.

Authors:  R R Lobb; G Chi-Rosso; D R Leone; M D Rosa; S Bixler; B M Newman; S Luhowskyj; C D Benjamin; I G Dougas; S E Goelz
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

5.  Structural and functional studies of the endothelial activation antigen endothelial leucocyte adhesion molecule-1 using a panel of monoclonal antibodies.

Authors:  R Pigott; L A Needham; R M Edwards; C Walker; C Power
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

6.  Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis.

Authors:  V D D'Agati; G B Appel; D Estes; D M Knowles; C L Pirani
Journal:  Kidney Int       Date:  1986-10       Impact factor: 10.612

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.

Authors:  E J ter Borg; G Horst; E J Hummel; P C Limburg; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1990-05

9.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

10.  Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis.

Authors:  R P Wuthrich; A M Jevnikar; F Takei; L H Glimcher; V E Kelley
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

View more
  44 in total

Review 1.  Biomarkers in systemic lupus erythematosus.

Authors:  Gabor G Illei; Peter E Lipsky
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

2.  Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis.

Authors:  Adnan N Kiani; Tianfu Wu; Hong Fang; Xin J Zhou; Chul W Ahn; Laurence S Magder; Chandra Mohan; Michelle Petri
Journal:  J Rheumatol       Date:  2012-04-15       Impact factor: 4.666

3.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

4.  Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.

Authors:  Juan M Mejia-Vilet; Samir V Parikh; Huijuan Song; Paolo Fadda; John P Shapiro; Isabelle Ayoub; Lianbo Yu; Jianying Zhang; Norma Uribe-Uribe; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2019-07-01       Impact factor: 5.992

5.  Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus.

Authors:  H Rahimi; K Maurer; L Song; E Akhter; M Petri; K E Sullivan
Journal:  Lupus       Date:  2013-03       Impact factor: 2.911

6.  Evaluation of Endothelial Cell Adhesion Molecules and Anti-C1q Antibody in Discriminating between Active and Non-Active Systemic Lupus Erythematosus.

Authors:  Hasni Mahayidin; Nurul Khaiza Yahya; Wan Syamimee Wan Ghazali; Asmahan Mohd Ismail; Wan Zuraida Wan Ab Hamid
Journal:  Malays J Med Sci       Date:  2016-05

7.  Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.

Authors:  Erin Kim; Joan Cook-Mills; Gabrielle Morgan; Simone T Sredni; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2012-11

Review 8.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

Review 9.  Neurologic manifestations of systemic lupus erythematosus in children and adults.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

10.  Atherosclerosis risk factors in systemic lupus erythematosus.

Authors:  Surabhi Agarwal; Jennifer R Elliott; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.